Key Highlights

  • Hydrix Services recorded quarterly Revenue of A$2.8 million, up 28.1% on the previous quarter and 11.6% on the prior corresponding quarter.
  • Hydrix Medical recorded a A$0.65 million contract sale of its Implicity remote cardiac monitoring platform to the National Heart Centre Singapore.
  • The company appointed a US-based Vice President of Business Development to support sales growth.
  • Cash was about A$1.5 million at quarter end, according to the company's Cash Flow table.

Hydrix Limited (ASX:HYD) released its September quarter trading and operational update on 29 October 2026. The company reported year-on-year quarterly revenue growth, contract sales in its engineering services business, the first commercial sale of its Implicity remote cardiac monitoring platform in the Asia-Pacific region, and progress on its defence technology strategy.

Hydrix Services

Contract sales were A$4.1 million and quarterly revenue was A$2.8 million, up 28.1% on the previous quarter and 11.6% on the prior corresponding quarter. The company appointed a US-based Vice President of Business Development to accelerate sales growth.

Hydrix Medical and Implicity

Hydrix Medical recorded a A$0.65 million contract sale to the National Heart Centre Singapore. The company describes it as the first commercial sale of the Implicity remote cardiac monitoring platform in Asia-Pacific, and says it establishes a regional reference customer for future sales.

Hydrix Defence

The company reports a first major defence-related delivery during the quarter and says it continued to advance its defence technology commercialisation strategy. The update does not give the value of that delivery in the summary.

Sector Context and Risks to Watch

Medical device commercialisation depends on regulatory approvals, hospital adoption and reimbursement, and a single reference sale does not show a repeatable sales rate. Defence contracts also depend on government procurement timing.

The main risks are the conversion of the Implicity reference sale into recurring revenue, the timing of defence orders and the cost of expanding the US sales team. Future updates will show whether revenue growth continues.

Final Word

Hydrix reports higher quarterly revenue, a first regional medical sale and a defence programme delivery, with growth in its services contracts. The next updates are expected to show whether the Implicity sale leads to further orders and whether defence contracts continue.